Wall Street analysts are expecting that 23andMe's (NASDAQ: ME) stock will hit around $5.69 within a year, which means they think it can grow to more than double its current price of $2.61. In 2019, it reported sales of $156.3 million, which means that its compound annual growth rate (CAGR) from 2019 through 2024 would be 31.3%.